Previous 10 | Next 10 |
BOSTON and LONDON, May 02, 2022 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced it has reached an agreement with Gesetzliche Krankenversicherung Spitzenverband (GKV-SV) which will result in reimbursed access to Libmeldy ® (atid...
BOSTON and LONDON, April 11, 2022 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced it has reached another historic reimbursement agreement with the Italian Medicines Agency, also known as Agenzia Italiana del Farmaco (AIFA), to enable ac...
Orchard Therapeutics PLC (ORTX) Q4 2021 Earnings Conference Call March 30, 2022 8:00 AM ET Company Participants Bobby Gaspar – Chief Executive Officer and Co-Founder Braden Parker – Chief Commercial Officer Frank Thomas – President and Chief Operating Officer Conference C...
Orchard Therapeutics (ORTX -3.3%) reported its Q4 result and said it plans to refine its portfolio and undertake a 30% proposed workforce reduction. The company said it plans to focus its hematopoietic stem cell (HSC) gene therapy platform exclusively on severe neurometabolic diseases an...
Libmeldy European launch momentum building with multiple MLD patients treated and strong recognition of value proposition; U.S. BLA filing of OTL-200 on track for late 2022 / early 2023 Broad research platform presents opportunities for larger indications and partnerships; precl...
AER, ATAI, BNTX, CAAS, CWCO, OTCPK:DLMAF, OTCQX:KNTNF, LGMK, MSM, ORTX, PAYX, PTE, OTCQX:TCNNF, TCRT, UPH For Seeking Alpha's full earnings season calendar, click here. For further details see: Notable earnings before Wednesday's open
BOSTON and LONDON, March 24, 2022 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced that the company will host a conference call and live webcast on Wednesday, March 30, 2022, at 8:00 a.m. ET to review business updates and its fourth quar...
BOSTON and LONDON, March 03, 2022 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced that members of the management team will present at the following investor conferences: Cowen 42 nd Annual Healthcare Conference on March 8, 2...
BOSTON and LONDON, Feb. 07, 2022 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today outlined five upcoming presentations from across its neurodegenerative portfolio to be featured at the 18th Annual WORLD Symposium ™ being ...
Buying Penny Stocks Today? Here’s What You Need to Know Yesterday, we witnessed many penny stocks and blue chips fall substantially. This was led by Meta, the parent company of Facebook, dropping in value by more than 26%. As a result, the tech heavy NASDAQ, dropped by over 3.7% ...
News, Short Squeeze, Breakout and More Instantly...
Orchard Therapeutics plc Company Name:
ORTX Stock Symbol:
NASDAQ Market:
Orchard Therapeutics plc Website:
TOKYO, LONDON and BOSTON, May 03, 2024 (GLOBE NEWSWIRE) -- Orchard Therapeutics, recently acquired by Kyowa Kirin with the goal of accelerating the delivery of new gene therapies to patients around the globe, today announced that Bobby Gaspar, M.D., Ph.D., co-founder and chief executive officer, ...
Crescent Energy Company Class A (CRGY) is expected to report $0.21 for Q4 2023 ThredUp Inc. (TDUP) is expected to report $-0.13 for Q4 2023 Wright Investors` Service Holdings Inc (IWSH) is expected to report for Q4 2023 Bridgford Foods Corporation (BRID) is expected to report for Q1 2...
Gene therapy being developed as a one-time treatment to address the underlying cause of the disease by inserting a functional copy of the human IDUA gene into a patient’s own hematopoietic stem cells HURCULES study to enroll 40 patients at clinical sites across the U.S....